Drug Profile
NVX 308
Alternative Names: NVX-308Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator NuvOx Pharma
- Class Fluorocarbons
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Myocardial-infarction in USA (IV)
- 02 Jul 2020 NVX 308 is still in preclinical development for Myocardial-infarction in USA (IV) (NuvOx Pharma pipeline, July 2020)
- 31 Aug 2014 Preclinical trials in Myocardial infarction in USA (IV)